[go: up one dir, main page]

WO2011150073A3 - Compositions comprenant le domaine nc2 du collagène ix et leurs procédés d'utilisation - Google Patents

Compositions comprenant le domaine nc2 du collagène ix et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2011150073A3
WO2011150073A3 PCT/US2011/037923 US2011037923W WO2011150073A3 WO 2011150073 A3 WO2011150073 A3 WO 2011150073A3 US 2011037923 W US2011037923 W US 2011037923W WO 2011150073 A3 WO2011150073 A3 WO 2011150073A3
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
domain
compositions
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/037923
Other languages
English (en)
Other versions
WO2011150073A2 (fr
Inventor
Hans Peter Bachinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shriners Hospitals for Children
Original Assignee
Shriners Hospitals for Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shriners Hospitals for Children filed Critical Shriners Hospitals for Children
Priority to CA2800595A priority Critical patent/CA2800595C/fr
Publication of WO2011150073A2 publication Critical patent/WO2011150073A2/fr
Publication of WO2011150073A3 publication Critical patent/WO2011150073A3/fr
Priority to US13/684,310 priority patent/US9315561B2/en
Anticipated expiration legal-status Critical
Priority to US15/132,453 priority patent/US9932390B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B24/00—Use of organic materials as active ingredients for mortars, concrete or artificial stone, e.g. plasticisers
    • C04B24/12—Nitrogen containing compounds organic derivatives of hydrazine
    • C04B24/14—Peptides; Proteins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Ceramic Engineering (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne la capacité d'amorce de trimérisation et de détermination d'empilement nouvellement identifiée du domaine NC2 du collagène IX. L'invention porte également sur un bloc de construction moléculaire hexavalent où la liaison de fractions supplémentaires aux terminaisons amino et carboxyle de monomères comprenant le domaine NC2 du collagène IX favorise l'association dirigée desdites fractions grâce à la capacité de détermination d'empilement et d'amorce de trimérisation du domaine NC2 du collagène IX.
PCT/US2011/037923 2010-05-26 2011-05-25 Compositions comprenant le domaine nc2 du collagène ix et leurs procédés d'utilisation Ceased WO2011150073A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2800595A CA2800595C (fr) 2010-05-26 2011-05-25 Compositions comprenant le domaine nc2 du collagene ix et leurs procedes d'utilisation
US13/684,310 US9315561B2 (en) 2010-05-26 2012-11-23 Compositions comprising the NC2 domain of collagen IX and methods of using same
US15/132,453 US9932390B2 (en) 2010-05-26 2016-04-19 Compositions comprising the NC2 domain of collagen IX and methods of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34873510P 2010-05-26 2010-05-26
US61/348,735 2010-05-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/684,310 Continuation US9315561B2 (en) 2010-05-26 2012-11-23 Compositions comprising the NC2 domain of collagen IX and methods of using same

Publications (2)

Publication Number Publication Date
WO2011150073A2 WO2011150073A2 (fr) 2011-12-01
WO2011150073A3 true WO2011150073A3 (fr) 2012-04-05

Family

ID=45004767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/037923 Ceased WO2011150073A2 (fr) 2010-05-26 2011-05-25 Compositions comprenant le domaine nc2 du collagène ix et leurs procédés d'utilisation

Country Status (3)

Country Link
US (2) US9315561B2 (fr)
CA (1) CA2800595C (fr)
WO (1) WO2011150073A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150073A2 (fr) * 2010-05-26 2011-12-01 Shriners Hospitals For Children Compositions comprenant le domaine nc2 du collagène ix et leurs procédés d'utilisation
WO2014168986A1 (fr) 2013-04-08 2014-10-16 Brown Dennis M Bénéfice thérapeutique de composés chimiques administrés de façon sous-optimale
WO2017019806A2 (fr) * 2015-07-27 2017-02-02 Michael Fox Collagène xix, formulation de celui-ci et procédés de traitement de troubles associés aux synapses neuronales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925736A (en) * 1995-01-10 1999-07-20 Fibrogen, Inc. Collagen-based methods and formulations for the treatment of arthritis
BR9611547A (pt) 1995-11-13 1999-06-15 Fibrogen Inc Proteína de fusão processos para produzir proteína de fusão humana recombinante e colágeno tipo ix humano recombinante
US7268116B2 (en) * 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
US7405037B2 (en) * 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
EP1937701A4 (fr) * 2005-09-02 2009-09-16 Colbar Lifescience Ltd Matrices de polysaccharides et de proteines reticulees et leurs procedes de preparation
US20070264687A1 (en) * 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
WO2011150073A2 (fr) * 2010-05-26 2011-12-01 Shriners Hospitals For Children Compositions comprenant le domaine nc2 du collagène ix et leurs procédés d'utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOUDKO, S.P. ET AL.: "Crystal Structure of Human Collagen XVIII Trimerization Domain: a Novel Collagen Trimerization Fold", J. MOL. BIOL., vol. 392, no. 3, 25 September 2009 (2009-09-25), pages 787 - 802 *
BOUDKO, S.P. ET AL.: "The NC2 Domain of Collagen IX Provides Chain Selection and Heterotrimerization", J. BIOL. CHEM., vol. 285, no. 31, 30 July 2010 (2010-07-30), pages 23721 - 23731 *
BOUDKO, S.P. ET AL.: "Trimerization and Triple Helix Stabilization of the Collagen XIX NC2 Domain", J. BIOL. CHEM., vol. 283, no. 49, 5 December 2008 (2008-12-05), pages 34345 - 34351 *
YU, Z. ET AL.: "Noncollagenous region of the streptococcal collagen-like protein is a trimerization domain that supports refolding of adjacent homologous and heterologous collagenous domains", PROTEIN SCI., vol. 19, 16 February 2010 (2010-02-16), pages 775 - 785 *

Also Published As

Publication number Publication date
US9932390B2 (en) 2018-04-03
CA2800595A1 (fr) 2011-12-01
US20160222089A1 (en) 2016-08-04
WO2011150073A2 (fr) 2011-12-01
CA2800595C (fr) 2018-04-24
US20130157257A1 (en) 2013-06-20
US9315561B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
BR112012002117A2 (pt) composições poliméricas modificadas de ácido hialurônico e métodos relacionados.
EP2560684A4 (fr) Échafaudages multimériques à base de domaine de fibronectine de type iii
JOP20180102A1 (ar) مركب صيدلاني
WO2012058211A3 (fr) Dérivés quinazoline, compositions et utilisations correspondantes
MY156182A (en) Resin composition
WO2014076321A8 (fr) Nouveaux polypeptides de liaison spécifique et leurs utilisations
EP2351575A4 (fr) Nouvelles utilisations des protéines grs ou de leurs fragments
MX336277B (es) Composicion a base de monomeros de acido sulfonico.
ZA201206969B (en) Fibronectin based scaffold domain proteins that bind il-23
EA201070270A1 (ru) Пептиды с пониженным уровнем образования димеров
MA34025B1 (fr) Polypeptides se liant au bêta-a
DK2370474T3 (da) Fremgangsmåde til fremstilling af hyaluronsyrefunktionaliserede derivater og dannelse af hydrogeler deraf
GEP20156341B (en) Anticoagulant antidotes
EP2308045A4 (fr) Compression de facteurs d'échelle audio par transformation bidimensionnelle
WO2010004377A8 (fr) Compositions de revêtement antireflets
UA112416C2 (uk) Антитіло до fap і способи його застосування
BR112013011627A2 (pt) composição de inibição da corrosão
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
WO2012061480A3 (fr) Compositions et procédés pour l'administration d'agents thérapeutiques
BRPI1010608A2 (pt) poliéster silano-funcional em composições de cura de umidades baseadas em polímeros silano-funcionais.
MX2015017334A (es) Uso de un polímero de acrilato de 2-octilo como agente de enlace en una composición de recubrimiento.
EP4534115A3 (fr) Biomatériaux injectables
WO2013003675A3 (fr) Additif adhésif
BR112013009033A2 (pt) composições de revestimento com propriedades anti-corrosão
WO2011095331A3 (fr) Préparation cosmétique et utilisation de celle-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11787336

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2800595

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11787336

Country of ref document: EP

Kind code of ref document: A2